The A2 pulley rupture is the climber’s ACL - the season-ending injury everyone has either had or is one bad crimp away from. A small ligamentous band at the proximal phalanx, holding the finger flexor tendon close to the bone, ruptured during a max-effort crimp on a small hold. Recovery is 6 weeks for a partial tear, 6+ months for a complete rupture with bowstringing. The structure has limited blood supply, re-injures easily during return-to-climbing, and is exactly the kind of tendon-pulley target the pre-clinical BPC-157 literature has been mapped onto in climbing forums for years. This piece walks through the overlap.
Research framing throughout. New-U supplies all compounds named below strictly as laboratory reagents - not for human consumption, athletic application, or competition use. BPC-157 and TB-500 are on the WADA Prohibited List under category S2.
Climbing’s damage profile is unusual: extreme load on very small structures, repeated thousands of times over a session, and asymmetric across the hands. The fingers take more abuse than any other structure in the sport.
| Structure | What climbing does | Recovery timeline |
|---|---|---|
| A2 pulley | The proximal phalanx pulley loaded to ~3x bodyweight on a single finger crimp; ruptures during max-effort moves on small holds | 6–12 weeks (partial); 6+ months (complete rupture, sometimes surgical) |
| A4 pulley | Distal phalanx pulley; less commonly injured but more disabling when ruptured | Often surgical; 6+ months recovery |
| FDP / FDS flexor tendons | Repetitive loading; partial tears in serious crimpers | 4–8 weeks; chronic in high-volume climbers |
| Lumbrical muscles | Open-handed grip on slopers and pockets loads them eccentrically | 2–6 weeks |
| Elbow tendons (medial / lateral epicondyle) | Climber’s elbow is among the most common chronic injuries | 3–6 months for chronic tendinosis resolution |
| Shoulder labrum / rotator cuff | Overhead loading, gaston moves, dynamic catches | Often chronic; surgical in severe cases |
| Skin (fingertips) | Repetitive friction loss; finger flapper rate in granite or finger-jamming routes | 3–14 days for healing; chronic callus management |
| Mental recovery / fear-of-injury | The psychological cost of injury recovery; return-to-climbing risk-aversion | Weeks to permanent depending on injury severity |
The A2 pulley is the headline because it is both common and disabling. A serious bouldering or sport-climbing career typically includes one or more A2 events. The recovery is so long, and the re-injury rate during return so high, that anything that plausibly accelerates collagen remodelling has been studied informally in the climbing community for years.
IFSC & WADA warning. The IFSC (International Federation of Sport Climbing) tests under WADA at World Cup, World Championship and Olympic events. IFSC-affiliated national federations test their athletes. BPC-157 and TB-500 are listed under WADA category S2 (peptide hormones and growth factors). CJC-1295, ipamorelin and other GH-axis secretagogues are also under S2. Recreational outdoor climbing is unregulated but the legal status of the compounds does not change.
| Compound | Research mechanism | Climbing-relevant fit |
|---|---|---|
| BPC-157 | Angiogenesis (VEGFR2), collagen organisation, fibroblast migration | The headline. Pulleys and tendons are exactly the structures BPC-157’s animal-study mechanism targets. The most-discussed compound in climbing-forum injury threads. |
| TB-500 | Cell migration, actin regulation, broad soft-tissue mobilisation | The "Wolverine stack" partner. Studied alongside BPC-157 in pulley-recovery research conversations. |
| GHK-Cu | Collagen, elastin, connective-tissue density; modulates over 4,000 human genes | Skin resilience for high-volume climbers; secondary connective-tissue density support for the tendon-pulley system. |
| CJC-1295 + Ipamorelin | Growth-hormone axis; pulsatile GH release | Less commonly discussed in climbing than in MMA / powerlifting but mechanistically relevant for the GH-mediated tendon-collagen remodelling that any return-to-climbing programme needs. |
The mechanistic case is unusually clean for climbing: the pre-clinical literature describes effects on the exact tissue (tendon pulley collagen) that climbing damages most severely. The human-trial case is still non-existent. There are no randomised controlled trials testing any of these compounds against a finger-pulley recovery endpoint. The climbing-community evidence is overwhelmingly anecdotal n=1 case reports on forums (UKClimbing, MountainProject, /r/climbharder), not controlled clinical data.
The damage profile varies across climbing disciplines but the recovery target converges on the same structures. Bouldering concentrates damage in the fingers and shoulders (max-effort moves, frequent falls). Sport climbing adds elbow tendons and forearm pump damage (sustained pulls). Trad climbing adds skin abrasion and finger-jam injury (offwidths, hand cracks). Ice and mixed climbing stack tool-grip strain on top of all of the above. The peptide-research conversation is broadly similar across all four; the only meaningful difference is that ice climbers add a connective-tissue-density discussion (GHK-Cu) for the chronic cold-tissue stress that is otherwise rare in climbing.
Sealed vials of BPC-157, TB-500, GHK-Cu and the wider research catalog, independently verified at >99% purity by Janoshik and Freedom Diagnostics. Research use only - not for human consumption. Banned in WADA / IFSC-tested competition.
Browse the catalog